Clinically approved treatments for neurological disorders induced by mitochondrial dysfunction
| Drug name | Activity | Clinical trial number |
|---|---|---|
| EPI-743 | Antioxidant | NCT01721733 |
| KH176 | Antioxidant | NCT02544217 |
| RP103 (cysteamine bitartrate delayed release) | Cystine-depleting agent | NCT02023866 |
| Idebenone | Antioxidant | NCT00887562 |
| RP103 (cysteamine bitartrate delayed release) | Cystine-depleting agent | NCT02473445 |
| Medium chain triglycerides | Shift heteroplasmy | NCT01252979 |
| L-arginine | NO precursor | NCT01603446 |
| L-arginine (IV) | NO precursor | JMA-IIA00023 |
| L-arginine (PO) | NO precursor | JMA-IIA00025 |
| Arginine and citrulline | NO precursor | NCT01339494 |
| Taurine | Taurine modification | UMIN000011908 |
| Pyruvate | NAD donor | JMA-IIA00093 |
| DCA | Lowering lactate levels | NCT00068913 |
DCA: dichloroacetate; NO: nitric oxide